# Study of Netarsudil Ophthalmic Solution in Subjects With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)

> **NCT03233308** · PHASE2 · COMPLETED · sponsor: **Aerie Pharmaceuticals** · enrollment: 20 (actual)

## Conditions studied

- Primary Open Angle Glaucoma or Ocular Hypertension

## Interventions

- **DRUG:** Netarsudil Ophthalmic Solution 0.02%
- **OTHER:** Placebo Comparator

## Key facts

- **NCT ID:** NCT03233308
- **Lead sponsor:** Aerie Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-10-20
- **Primary completion:** 2018-04-19
- **Final completion:** 2018-04-19
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2019-08-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03233308

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03233308, "Study of Netarsudil Ophthalmic Solution in Subjects With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT03233308. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*